Drug details
Ocrevus (ocrelizumab injection)
type of Monoclonal Antibodies
Ocrevus (ocrelizumab) injection is aCD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.
This drug may have the following side effects:
- hives,
- nausea,
- rash,
- fever,
- shortness of breath,
- tiredness,
- dizziness,
- headache,
- coughing,
- fatigue,
- trouble breathing,
- wheezing, and
- swelling of the throat,
- itchy skin,
- throat irritation or pain,
- feeling faint,
- fast heart beats,
- redness on your face (flushing)
The following drugs are related to Ocrevus, either as a replacement or used together:
- Ampyra (dalfampridine extended-release tablets)
- Aubagio (teriflunomide tablets)
- Avonex (interferon beta-1a)
- Imuran (azathioprine)
- Lyvispah (baclofen oral granules)
- Ozobax (baclofen oral solution)
- Fleqsuvy (baclofen oral suspension)
- Bafiertam (monomethyl fumarate delayed-release capsules)
- Betaseron (interferon beta-1b)
- Briumvi (ublituximab-xiiy injection)
- Mavenclad (cladribine tablets)
- Zinbryta (daclizumab for injection)
- Tecfidera (dimethyl fumarate delayed release capsules)
- Vumerity (diroximel fumarate delayed-release capsules)
- Enbrel (etanercept)
- Extavia (interferon beta-1b kit)
- Gilenya (fingolimod capsules)
- Tascenso ODT (fingolimod orally disintegrating tablets)
- Rebif (interferon beta-1a)
- Kesimpta (ofatumumab injection)
- Mayzent (siponimod tablets)
- Novantrone (mitoxantrone for injection concentrate)
- Tysabri (natalizumab)
- Zeposia (ozanimod capsules)
- Plegridy (peginterferon beta-1a injection for subcutaneous use)